In cholangiocarcinoma cell lines, FGF5 was recently implicated in activation of the Hippo pathway and it was suggested that Hippo pathway activation, assessed via YAP expression, could serve as potential biomarker to identify patients with a higher likelihood of responding to therapies targeting the FGF/FGFR axis [35]. Here, FGF5 is linked to cholangiocarcinoma.